This work is licensed under a Table 3.
Changes of endocrinological parameters after metyrosine (αMPT) administration or surgical treatment.
| Parameters | Pretreatment | After-αMPT | After surgery | αMPT/pretreatmentb | Surgery/pretreatmentc | ||
|---|---|---|---|---|---|---|---|
| Change rate, % | P | Change rate, % | P | ||||
| Prolactin, ng/dL | 12.7 (7.5–17.7)d (n = 9) | 39.4 (25.3–55.5)d (n = 9) | 17.4 (13.0–25.7) (n = 8) | 251.7 ± 141.6 | <0.001 | 46.4 (37.8–145.9) | 0.016 |
| TSH, μU/mL | 0.90 (0.59–2.69) (n = 10) | 1.54 (1.32–3.17) (n = 10) | 2.16 (0.71–4.08)a (n = 8) | 72.0 ± 76.4 | 0.024 | 26.2 ± 64.8 | 0.37 |
| Free thyroxine, ng/dL | 1.06 ± 0.19 (n = 10) | 1.05 ± 0.20 (n = 10) | 1.17 ± 0.30 (n = 8) | −0.6 ± 9.9 | 0.43 | 2.6 (−2.3 to 30) | 0.11 |
| Growth hormone, ng/dL | 0.47 (0.08–3.12) (n = 9) | 0.37 (0.07–0.84)a (n = 9) | 0.48 (0.19–2.35) (n = 9) | −55.0 (−84.8 to 50.4) | 0.098 | 149.5 ± 227.6 | 0.68 |
| IGF1, s.d. valued | −1.2 ± 0.6 (n = 8) | −1.1 ± 0.7 (n = 8) | −1.6 ± 0.8 (n = 8) | 0.1 ± 0.8 | 0.70 | 0.7 (−0.2 to 1.7) | 0.007 |
| PRA, ng/mL/h | 1.1 (0.6–2.4)a (n = 10) | 0.4 (0.2–0.7) (n = 10) | 0.3 (0.2–0.7) (n = 9) | −73.2 (−78.7 to −32.1) | 0.010 | −44.4 (−90.2 to −23.2) | 0.022 |
| PAC, pg/mL | 140.4 ± 55.6 (n = 10) | 102.3 ± 43.7 (n = 10) | 90.4 ± 33.0 (n = 9) | −14.5 ± 52.8 | 0.93 | −23.1 ± 34.5 | 0.038 |
| ARR (PAC/PRA) | 114 (88–184) (n = 10) | 180 (120–574) (n = 10) | 217 (100–681)a (n = 9) | 83.8 (31.5–192.5) (n = 10) | 0.009 | 58.8 (−6.4 to 532.6) (n = 9) | 0.037 |
Normally distributed and non-normally distributed variables are presented as the mean ± s.d. and the median (interquartile range), respectively. aNormally distributed variables; however, presented as median (interquartile range) to compare with non-normal distributed variables. bChange rates were calculated as (post-αMPT value – pre-αMPT value)/pre-αMPT value × 100%. cChange rates were calculated as (postsurgery value – pre-αMPT value)/pre-αMPT value × 100%. dIGF1 value is presented as s.d. value standardized by sex and age. Each value was analyzed using a paired t-test and Wilcoxon’s signed-rank test for normally and non-normally distributed variables, respectively. P-values of <0.05 are considered significant (bold).
αMPT, α-methyl-para-tyrosine (metyrosine); ARR, aldosterone-to-renin ratio; IGF1, insulin-like growth factor 1; PAC, plasma aldosterone concentration; PRA, plasma renin activity; PRL, prolactin; TSH, thyroid stimulation hormone